Therios 750 mg Palatable Tablets for Dogs

Main information

  • Trade name:
  • Therios 750 mg Palatable Tablets for Dogs
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Therios 750 mg Palatable Tablets for Dogs
    Hungary
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Cefalexin
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0347/002
  • Authorization date:
  • 04-01-2011
  • EU code:
  • UK/V/0347/002
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:May2012

AN:00601/2011

Page-1-of6

SUMMARYOFPRODUCTCHACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

UK,AT,IE,PL,CZ,BE,

HU,GK,LUX,NL,PT Therios750mgpalatabletabletsfordogs

IT,ES,FI Therios750mgflavouredtabletsfordogs

Therios750mgaromatisierteTablettenfürHunde

NO Therios750mg,tyggetabletttilhund.

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Activesubstance:

Eachtabletcontains:

Cefalexin(ascefalexinmonohydrate)...........................750mg

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Tablet

Roundscoredbeigepalatabletablet

Thetabletcanbedividedintoequalhalvesandquarters

4. CLINICALPARTICULARS

4.1Targetspecies

Dogs

4.2Indicationsforuse,specifyingthetargetspecies

Forthetreatmentofbacterialskininfectionsindogs(includingdeepand

superficialpyoderma)causedbyorganismssensitivetocefalexin.

Forthetreatmentofurinarytractinfectionsindogs(includingnephritisandcystitis)

causedbyorganismssensitivetocefalexin.

4.3Contraindications

Donotuseinanimalswhichareknowntobehypersensitivetopenicillins.

Donotuseincaseofsevererenalfailure

Donotuseinrabbits,guineapigs,hamstersandgerbils.

4.4Specialwarningsforeachtargetspecies

None.

Revised:May2012

AN:00601/2011

Page-2-of6

4.5Specialprecautionsforuse

i. Specialprecautionsforuseinanimals

Aswithotherantibioticswhichareexcretedmainlybythekidneys,systemic

accumulationmayoccurwhenrenalfunctionisimpaired.Incaseofknown

renalinsufficiencythedoseshouldbereduced.

Theproductisnotrecommendedforuseindogslessthan6kgbodyweight.

Whereverpossible,theuseoftheproductshouldbebasedonsusceptibility

testingandtakeintoaccountofficialandlocalantimicrobialpolicies.

Safetyoftheexcipient,ammoniumglycyrrhizate,hasnotbeenestablishedin

dogslessthan1yearold.

ii. Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Cephalosporinsmaycausesensitization(allergy)followinginjection,

inhalation,ingestionorskincontact.Sensitivitytopenicillinsmayleadto

crosssensitivitytocephalosporinandviceversa.Allergicreactionstothese

substancesmayoccasionallybeserious.

1.Donothandlethisproductifyouknowyouaresensitizedorifyouhave

beenadvisednottoworkwithsuchpreparations.

2.Handlethisproductwithgreatcaretoavoidexposure,takingall

recommendedprecautions.Washhandsafteruse.

3.Ifyoudevelopsymptomsfollowingexposuresuchasskinrashyoushould

seekmedicaladviceandshowthedoctorthiswarning.Swellingsoftheface,

lipsoreyesordifficultybreathingaremoreserioussymptomsandrequire

urgentmedicalattention.

Intheeventofaccidentalingestion,particularlybyachild,seekmedial

attentionandshowthedoctortheleaflet

4.6Adversereactions(frequencyandseriousness)

Vomitinganddiarrhoeahavebeenobservedindogs.Inrarecases

hypersensitivitycanoccur.

4.7Useduringpregnancy,lactationorlay

Donotuseinpregnantorlactatingbitches.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Inordertoensureefficacy,theproductshouldnotbeusedincombinationwith

bacteriostaticantibiotics.

Revised:May2012

AN:00601/2011

Page-3-of6

Concurrentuseoffirstgenerationcephalosporinswithaminoglycosideantibiotics

orsomediureticssuchasfurosemidecanenhancenephrotoxicityrisks

4.9Amountstobeadministeredandadministrationroute

Fororaladministration.

15mgcefalexinperkgbodyweighttwicedaily(equivalentto30mgperkg

bodyweightperday)fordurationof:

-14daysincasesofurinarytractinfection

-Atleast15daysincasesofsuperficialinfectiousdermatitis

-Atleast28daysincasesofdeepinfectiousdermatitis

Insevereoracuteconditionsthedosemaybesafelydoubledto30mg/kgtwice

daily.Toallowforaccuracyofdosing,tabletscanbehalvedorquartered.

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyas

possibletoavoidunderdosing.

Theriostabletsarewellacceptedbydogsbutmaybecrushedoraddedtoasmall

quantityoffoodimmediatelypriortofeedingifnecessary

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Trialsperformedonanimalswithupto5timestherecommendedtwicedaily

dosageof15mg/kgdemonstratedthatcefalexinwaswelltolerated.

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:Antibacterialforsystemicuse,first-generation

cephalosporin

ATCvetcode:QJ01DB01

Cefalexinmonohydrate,theactiveingredientoftheTheriostablets,isa

bactericidalantibioticofthecephalosporinfamily,obtainedbyhemi-synthesisof

the7amino-cephalosporanicnucleus.

5.1Pharmacodynamicproperties

Cefalexinactsbyinhibitingthenucleopeptidesynthesisofthebacterialwall.

Cephalosporinsinterferewithtranspeptidationbyacylatingtheenzymemakingit

unabletocross-linkmuramicacid-containingpeptidoglycanstrands.Theinhibition

ofthebiosynthesisofthematerialrequiredtobuildthecellwallresultsina

defectivecellwallandconsequentlyosmoticallyunstabletoprotoplasts.The

combinedactionresultsincelllysisandfilamentformation.Cefalexinisactive

Revised:May2012

AN:00601/2011

Page-4-of6

againstGrampositiveandGramnegativebacteriasuchasStaphylococcusspp

(includingpenicillin-resistantstrains),Streptococcusspp.,.,Escherichia.coli,and

Klebsiellaspp,.Cefalexinisnotinactivatedbybeta-lactamasesproducedby

Grampositivebacteria.However,beta-lactamasesproducedbygram-negative

bacteriacaninhibitcefalexinbyhydrolysisofthebeta-lactamcycle.Resistanceis

transmittedbyplasmidicorchromosomicroute.

Cefalexinisnotinactivatedbythestaphylococcalbeta-lactamasesbuthasa

moderateactivityagainstnon-transferable(chromosomal)beta-lactamase

producinggram-negativeenterobacteriacceaeandfastidiousgram-negatives.No

antibacterialactivityisobtainedagainstEnterobacterspp.,P.aeruginosaand

Serratiaspp.

Cefalexinhasatime-dependentbactericidalactivityagainstStaphylococcusspp

andPasteurellamultocida.

Thecefalexincriticalbreakpoints(MICvalue)forpathogensofveterinary

importanceweresetupat:

- Susceptible:≤8mg/L

-Resistant:>32mg/L

Staphylococcusspp,Streptococcusspp,E.coliandKlebsiellasppandP.

multocidaaresusceptibletocefalexin.MIC90valuesforcefalexindeterminedin

targetbacterialstrainsisolatedfromdiseaseddogsinEuropeandintheUSAare:

-S.pseudintermedius:2µg/mL

-S.aureus:8µg/mL

-S.canis ≤0.5µg/mL

-Beta-hemolyticStreptococcusspp:2µg/mL

-E.coli:16µg/mL

-P.multocida:2µg/mL

-Klebsiella.spp:4µg/mL

Resistancetocefalexinmaybeduetooneofthefollowingmechanismsof

resistance.Firstly,theproductionofvariousbeta-lactamases(cephalosporinase),

thatinactivatetheantibiotic,isthemostprevalentmechanismamonggram-

negativebacteria.Secondly,adecreasedaffinityofthePBPs(penicillin-binding

proteins)forbeta-lactamdrugsisfrequentlyinvolvedforbeta-lactamresistant

gram-positivebacteria.Lastly,effluxpumps,extrudingtheantibioticfromthe

bacterialcell,andstructuralchangesinporins,reducingpassivediffusionofthe

drugthroughthecellwall,maycontributetoimprovetheresistantphenotypeofa

bacterium.

Well-knowncross-resistance(involvingthesameresistancemechanism)exists

betweenantibioticsbelongingtothebeta-lactamgroupduetostructural

similarities.Itoccurswithb-lactamasesenzymes,structuralchangesinporinsor

variationsineffluxpumps.Co-resistance(differentresistancemechanisms

involved)hasbeendescribedinE.coliduetoaplasmidharbouringvarious

resistancegenes.

5.2Pharmacokineticparticulars

Aftersingleoraladministrationoftherecommendeddosageof15mgcefalexin

perkgbodyweighttoBeagledogs,plasmaconcentrationswereobservedwithin

30minutes.Theplasmapeakwasobservedat1.33hwithaplasmaconcentration

of21.2µg/ml.Thebioavailabilityoftheactivewasover90%.Cefalexinwas

Revised:May2012

AN:00601/2011

Page-5-of6

detecteduntil24hoursaftertheadministration.Thefirsturinespecimenwas

collectedwithin2to12hourswithpeakconcentrationsofcefalexinmeasuredat

430to2758µg/mlwithin12hours.

Afterrepeatedoraladministrationofthesamedosage,twiceadayfor7days,

plasmapeaksoccurred2hourslaterwithaconcentrationof20µg/ml.Overthe

treatmentperiodconcentrationsweremaintainedabove1µg/ml.Themean

eliminationhalflifeis2hours.Skinlevelswerearound5.8to6.6µg/g2hours

aftertreatment.

5.3Environmentalproperties

Notapplicable.

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Croscarmellosesodium

Silica,colloidalanhydrous

Magnesiumstearate

Yeastdried

BiscuitflavourF07012

Ammoniumglycyrrhizate

Macrogol6000

6.2Incompatibilities

Noneknown

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years

Shelf-lifeafterfirstopeningtheimmediatepackaging:48hours.

Anydividedtabletportionsremainingafter48hoursshouldbediscarded.

6.4.Specialprecautionsforstorage

Donotstoreabove25

C

Dividedtabletsshouldbestoredintheblisterpack.

6.5Natureandcompositionofimmediatepackaging

Polyvinylchlorideblisterheatsealedwithanaluminiumcoverfoil.

Packsizes:

Cardboardboxwith1blisterof10tablets

Cardboardboxwith3blistersof10tablets

Cardboardboxwith20blistersof10tablets

Revised:May2012

AN:00601/2011

Page-6-of6

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductshouldbedisposedofinaccordancewithlocal

requirements

7. MARKETINGAUTHORISATIONHOLDER

SogevalSA

200avenuedeMayenne –BP2227

53022LAVALCedex9

France

Tel:33.2.43.49.51.51

Fax:33.2.43.53.97.00

E-mail: sogeval@sogeval.fr

8. MARKETINGAUTHORISATIONNUMBER

Vm 20749/4013

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Date:27 th

February2009

10.DATEOFREVISIONOFTHETEXT

Date:May2012

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Notapplicable

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

1-10-2018

Public Notification: FX75000 contains hidden drug ingredient

Public Notification: FX75000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use FX75000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

28-9-2018

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo International plc (NASDAQ: ENDP) today announced that one of its operating companies, Endo Pharmaceuticals Inc., is voluntarily recalling two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack to the consumer level. The products have been found to have incorrect daily dosing information on the label due to a labeling error which misstates the daily dose as "two to four tablets four times daily" rather than the correct dosage of "two tablets three times daily." (see pic...

FDA - U.S. Food and Drug Administration

There are no news related to this product.